Falun
Falun
Falun, Sweden60 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The HIt HArd and hiT Early in Multiple Sclerosis Trial | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 2 | 2026-10-08 | NCT07517185 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Shock, Systemic Inflammatory Response Syndrome, toxic shock syndrome | Recruiting | Not applicable | 2026-10-06 | NCT06140147 | |
| Cardiac Function in Swimming-Induced Pulmonary Edema (SIPE) | lung disorder, pulmonary edema, respiratory system disorder | Recruiting | Not stated | 2026-10-05 | NCT05391737 | |
| PEP-device for Treatment of Swimming-induced Pulmonary Edema (SIPE) | lung disorder, pulmonary edema, respiratory system disorder | Recruiting | Not applicable | 2026-10-05 | NCT05227222 | |
| O2 Versus CPAP Treatment Of Patients Undergoing SIPE Therapy (OCTOPUS) | lung disorder, pulmonary edema, respiratory system disorder | Recruiting | Not applicable | 2026-10-05 | NCT04307615 | |
| Patients With Long-stay at ICU: Factors and Evaluation - Feasibility Study | Confusion, Fatigue, Frailty, Neurobehavioral Manifestations, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, postintensive care syndrome | Not yet recruiting | Not stated | 2026-10-01 | NCT07851974 | |
| A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-10-01 | NCT07589634 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia | Birth Weight, Body Weight, Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications, Obstetric Labor, Premature, Pathological Conditions, Signs and Symptoms, Premature Birth, Signs and Symptoms, Urogenital Diseases, hypertension, pregnancy-induced, preeclampsia, pregnancy disorder | Recruiting | Phase 3 | 2026-09-28 | NCT06033131 | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-25 | NCT05552222 | |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05083169 | |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-21 | NCT06549595 | |
| Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism | Pulmonary Embolism Acute | Not yet recruiting | Phase 4 | 2026-09-17 | NCT07816978 | |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-16 | NCT07037459 | |
| Alloplastic Total Temporomandibular Joint (TMJ) Replacement Registry | Craniomandibular Disorders, Jaw Diseases, Mandibular Diseases, Stomatognathic Diseases, ankylosis, arthropathy, injury, muscle tissue disorder, musculoskeletal system disorder, temporomandibular joint disorder | Recruiting | Not stated | 2026-09-16 | NCT03991728 | |
| Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-10 | NCT05448547 | |
| A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 3 | 2026-09-09 | NCT07753993 | |
| eVISualisation of Physical Activity and Pain (eVIS) for Patients With Chronic Pain | Chronic Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not applicable | 2026-09-03 | NCT05009459 | |
| HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction | Digestive System Diseases, Gastrointestinal Hemorrhage, Hemorrhage, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, digestive system disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-09-02 | NCT05024864 | |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-08-27 | NCT06158841 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-08-24 | NCT07000357 | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-24 | NCT06152575 | |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-24 | NCT05020236 |